INTRODUCTION
T YPE 1 INTERFERONS (IFN) BELONG TO A FAMILY of structurally and functionally related molecules encoded by at least 13 different IFN-a genes and a single IFN-b gene. (1) The amino acid sequence homology between IFN-a subtypes is . 70%, whereas the sequence similarity between IFN-a and IFN-b is only , 25%. Type I IFN mediate a variety of pleiotropic effects on different cell types, of which its antiviral, antitumor, and immunomodulatory functions are well characterized. (2, 3) The reported immunomodulatory functions of type I IFN include major histocompatibility complex (MHC) class I upregulation on antigen presenting cells (APC), natural killer (NK) cell activation, T cell differentiation, and prevention of activation-induced apoptosis in T and B cells. (3) (4) (5) (6) Hence, type I IFN likely play a crucial role in initiating and maintaining both innate and adoptive humoral and cell-mediated immune responses.
IFN-a and IFN-b bind to a common type I IFN receptor that comprises two subunits, IFNAR-1 and IFNAR-2, which associate with IFN to form a ternary complex. (7) (8) (9) (10) (11) The major ligand binding subunit of the type I IFN receptor, IFNAR-2, exists in three forms derived from alternatively spliced mRNA transcripts encoded by the IFNAR-2 gene: soluble (IFNAR-2a), transmembrane short form (IFNAR-2b), and transmembrane long form (IFNAR-2c). (8, 9, 12) When IFN-a/b binds to their receptor, a series of tyrosine phosphorylation events is initiated, including activation of Janus-associated tyrosine kinases Jak1 and Tyk2, which are found associated with the type I IFN receptor complex. (13, 14) Activation of Jak1 and Tyk2 result in the tyrosine phosphorylation of Stat1 and Stat2 and in the formation of an IFN-stimulated gene factor 3 (ISGF3) transcription complex that consists of Stat1, Stat2, and p48 subunits. (15) (16) (17) Translocation of the ISGF3 complex to the nucleus and the subsequent binding to IFN-stimulated response elements (ISRE) leads to the activation of a variety of IFN-stimulated genes (ISG) that control the biologic actions of type I IFN. Although the Jak-Stat pathway of activation is well documented in mediating the biologic effects of type I IFN, there is evidence for the existence of other type I IFN signaling pathways that may control the biologic actions of type I IFN. (18, 19) Abnormal production of type I IFN is found to be associated with a number of autoimmune and inflammatory diseases, including systemic lupus erythematosus, (SLE), psoriasis, and rheumatoid arthritis. (20) (21) (22) In addition, type I IFN are implicated in allograft rejection and graft-versus-host disease (GVHD) following bone marrow transplantation. (23) (24) (25) Neutralization of type I IFN in these pathologic states may provide a therapeutic benefit. Monoclonal antibodies (mAb) derived against IFNAR-1 have been shown to neutralize the biologic effects of type I IFN in vitro. (26) (27) (28) An anti-IFNAR-1 mAb that neutralizes the biologic actions of type I IFN and blocks type I IFN binding, when used in combination with a subeffective dose of cyclosporine, prolonged long-term skin graft survival in cynomolgus monkeys. (29) Also anti-IFN-a/b antibodies administered together with a subeffective dose of cyclosporine have been shown to prolong cardiac allograft survival in rats. (30) To develop mAb to the type I IFN receptor that would neutralize multiple species of type I IFN, we evaluated a panel of mAb derived against the ligand binding subunit IFNAR-2. Two classes of anti-IFNAR-2 mAb were identified. One class of anti-IFNAR-2 mAb blocks IFN-a2a and IFN-b binding and inhibits the Jak-Stat pathway of activation. The other class of anti-IFNAR-2 mAb does not block IFN-a2a and IFN-b binding or the Jak-Stat pathway of activation yet inhibits the biologic actions of type I IFN and induces hyper-tyrosine phosphorylation of IFNAR-2. These results confirm the existence of Jak-Statindependent signaling pathways of type I IFN action and implicate hyper-tyrosine phosphorylation of IFNAR-2 as a regulator of this pathway.
MATERIALS AND METHODS

mAb
Hybridomas secreting mAb against the urinary form of soluble human IFNAR-2 were described previously. (8) Hybridomas were recloned and expanded. Sufficient amounts of culture supernatants containing anti-HuIFNAR-2 mAb were generated and purified by protein G affinity chromatography (Pharmacia, Piscataway, NJ). 
BIAcore binding
Anti-IFNAR-2 mAb were immobilized on BIAcore chips (Pharmacia, Piscataway, NJ) that had been constructed with rabbit antimouse Fc (RAMFc) by amine coupling using (1-ethyl-3- [3-dimethylaminopropyl] carbodiimide hydrochloride/N-hydroxysulfosuccinimide (EDC/NHS) and ethanolamine (BIAcore's amine coupling kit BR-1000-50). RAMFc (BIAcore P/N BR-1000-57) was diluted to 10 mg/ml with sodium acetate, pH 4. The carboxymethyl dextran surface of a CM-5 chip was activated with EDC/NHS for 5 min (25 ml), and then RAMFc solution was injected for 7 min at a flow rate of 5 ml/min (35 ml) . Unreacted active esters were quenched with 1 M ethanolamine, which was injected for 7 min (35 ml). After RAMFc immobilization, the surface was stabilized by injecting 25 mM HCl, 100 mM NaCl for 2 min (10 ml) six times. These coupling conditions give about 3400 RU of immobilized RAMFc. Anti-IF-NAR-2 mAb affinities for IFNAR-2 were determined in stack experiments. The running buffer was HBS (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% P20). In a stack experiment, anti-IFNAR-2 mAb (at 50 3 10 29 M unless otherwise specified) was washed onto the RAMFc surface, followed by IFNAR-2 concentrations that varied (10, 20, 50 , 100, 200, 500 nM) over the course of six data acquisition cycles. Kinetics data for the binding and dissociation of IFNAR-2 to anti-IFNAR-2 mAb were fit globally across all IFNAR-2 concentrations using nonlinear least squares analysis (BIAevaluation 3.0). In other stack experiments, binding of IFN-a2a (200 nM in 150 mM NaCl) or IFN-b (200 nM in 500 mM NaCl) to immobilized IFNAR-2/anti-IFNAR-2 complexes was evaluated.
[ 125 I]IFN-a2a cell binding
HuIFN-a2a (BioSource) was radiolabeled using the chloramine T method. Briefly, IFN-a2a (5.2 mg in 52 ml) was added to 1 mCi of [ 125 I] sodium iodide (NEN, Boston, MA) to which 20 ml chloramine T (1 mg/ml) was added and incubated at 4°C for 20 sec. The reaction was quenched by the sequential addition of 50 ml Na metabisulfite (5 mg/ml) and KI (5 mg/ml). [ 125 I] IFN-a2a was separated from free iodine using a PD-10 size exclusion column (Pharmacia) equilibrated with 0.25% gelatin in phosphate-buffered saline (PBS) and 0.02% sodium azide. The concentration of [ 125 I]IFN-a2a was determined by an IFN-a2a ELISA (BioSource), and specific activity was determined to be 2.1 3 10 10 cpm/nmol.
Bioassays
Antiviral assay. To determine antiviral activity, 4 3 10 4 WISH cells (ATCC, Rockville, MD) were seeded in 96-well flat-bottom plates (Becton Dickinson, Lincoln Park, NJ) in complete DMEM medium (GIBCO, Gaithersburg, MD) containing 10% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml penicillin/100 mg/ml streptomycin (CDMEM). On day 2, serial dilutions of anti-IFNAR-2 mAb were added to wells. After 2 h incubation at 37°C and 5% CO 2 , wells were treated with the indicated concentrations of HuIFN, followed by the addition of vesicular stomatitis virus (VSV) (ATCC) 6 h later. After 48 h at 37°C and 5% CO 2 , the extent of viral cytopathic effect was determined using MTT staining (Sigma, St. Louis, MO). Briefly, 25 ml of MTT solution at 5 mg/ml was dispensed to all wells. After a 2-h incubation at 37°C and 5% CO 2 , supernatants were removed, and wells were treated with 200 ml of 100% ethanol. After 15 min incubation at ambient temperature, optical densities (OD) were determined at 595 nm using Spectra MAX Microplate Spectrophotometer (Molecular Devices, Sunnyvale, CA).
Antiproliferation assay. Daudi cells (ATCC) were plated at 1 3 10 5 cells/well in 96-well, flat-bottom microtiter plates (Becton Dickinson) in RPMI 1640 medium (GIBCO) containing 10% heat-inactivated FBS, 2 mM glutamine, and 100 U/ml penicillin/100 mg/ml streptomycin. Cells were preincubated with serial dilutions of anti-IFNAR-2 mAb for 1 h at 37°C and 5%CO 2 before the addition of HuIFN. Cells were pulsed with 1 mCi/well [ 3 H]thymidine (NEN) for the last 18 h of a 72-h incubation at 37°C and 5% CO 2 . Plates were harvested using a Tomtec plate harvester, and the incorporated radioactivity was determined using the Wallac 1450 microbeta plus liquid scintillation counter (Wallac Oy, Turku, Finland).
MHC class I upregulation assay. Normal human dermal fibroblasts (CC-2511) (Clonetics, Walkersville, MD) were maintained in Fibroblast Basal medium with supplements (Clonetics) in T-175 flasks. For class I upregulation, assay cells were detached from the surface using trypsin (GIBCO), washed twice with Dulbecco's PBS (GIBCO), and resuspended in complete Fibroblast medium at 3.5 3 10 5 cells/well in 6-well plates (Becton Dickinson). Cells were cultured for 48 h at 37°C and 5% CO 2 in the presence of HuIFN or anti-IFNAR-2 mAb or both. After trypsinization, cells were washed and resuspended in FACS buffer (PBS containing 1% heat-inactivated FBS and 0.1% NaN 3 ). Cells were stained with 10 ml anti-HLA class 1 mAb (BioSource). After incubation at 4°C for 20 min, cells were washed with FACS buffer, and class I expression was evaluated by FACS analysis using a FACSCalibur flow cytometer (Becton Dickinson).
NK cell cytotoxicity assay. Human NK cell line NK9.2 was provided by Dr. J. Kornbluth (Arkansas Cancer Research Center, Little Rock, AR). (31) NK9.2 cells were plated at different ratios in 96-well round-bottom plates (Becton Dickinson). Cells were preincubated with serial dilutions of anti-IFNAR-2 mAb for 15 min at ambient temperature before addition of HuIFN, followed by an 18-h incubation at 37°C and 5% CO 2 . Cell-mediated cytotoxicity was assessed by measuring [
51 Cr] release in a 4-h test. Target cells in the exponential growth phase were incubated for 1 h with sodium chromate (100 mCi) (NEN) (SA 5 476.25 mCi/mg) at 37°C and 5% CO 2 , washed twice, and dispensed into the wells. After a 4-h incubation, 50 ml supernatant were mixed with 150 ml Supremix (Optiphase, Wallac), and [
51 Cr] release was determined in a Wallac microbeta counter (Wallac). Maximal [ 51 Cr] release was determined after treatment of wells with 1 N NaOH. Spontaneous release was determined from wells containing only target cells. Percent cytotoxicity was calculated as follows: % Cytotoxicity 5 100 3
Immunoprecipitations and immunoblotting. U-266 and Daudi cell lines (ATCC) were grown in log phase in RPMI 1640 medium containing 10% FBS, 2 mM glutamine, 100 IU/ml experimental cpm 2 spontaneous cpm } } } } maximum cpm 2 spontaneous cpm penicillin, and 100 mg/ml streptomycin. Cells were preincubated with 30 mg/ml indicated mAb and controls for 30 min at 4°C and then stimulated with various amounts of IFN for various times at 37°C and 5% CO 2 . Subsequently, cells were washed in cold PBS buffer containing 1 mM sodium orthovanadate, centrifuged, and lysed immediately in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.6, containing 150 mM NaCl, 1% Triton X-100, 10% glycerol, 0.2 mM sodium orthovanadate, 20 mM sodium fluoride, 1 mM phenyl methylsulfonyl fluoride [PMSF], 5 mg/ml leupeptin) for 15 min at 4°C. Insoluble material was removed by centrifugation, and postnuclear cell lysates were immunoprecipitated with 5 mg of the indicated polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA; New England Biolabs, Beverly, MA) and protein A/G plus beads (20 ml beads) overnight at 4°C. After five washes in lysis buffer containing 0.1% Triton X-100, the immunoprecipitates were denatured by boiling in SDS sample buffer containing 10% DTT and analyzed on NuPAGE Bis-Tricine (10%) or tris-acetate gels (4%-12%) (Novex). Gels were transferred to PVDF membranes (Novex, San Diego, CA), and blocked overnight in 5% bovine serum albumin (BSA) or I-Block (Tropix, Bedford, MA). Membranes were incubated for 2 h at ambient temperature with a 1:2500 dilution of antiphosphotyrosine mAb 4G10 (Upstate Biotechnology, Lake Placid, NY) and then washed three times with wash buffer containing 0.5% BSA and 0.1% Tween 20. Membranes were subsequently incubated with a 1:5000 dilution of goat antimouse Ig alkaline phosphatase reagent for 1 h at ambient temperature, washed three times in wash buffer, and developed using enhanced chemluminescence (ECL) (Tropix). Following dose-response and time course experiments with IFN-a2a and IFN-b, an IFN dose of 2000 IU was used to stimulate cells for 2 min for experiments on evaluation of anti-IFNAR-2 mAb.
Electrophoretic mobility shift assays (EMSA)
Daudi cells (4 3 10 6 in 1 ml RPMI 1640 medium) were preincubated with medium alone or with anti-IFNAR-2 mAb for 1 h at 37°C. The cultures were subsequently treated with 200 IU/ml IFN-b for 20 min at 37°C. The cells were washed three times with ice-cold PBS and immediately frozen in liquid nitrogen. The pellets were resuspended in three times their packed cell volume in a buffer containing 20 mM Tris, pH 7.6, 0.4 M NaCl, 0.2 mM EDTA, 20% glycerol, 1.5 mM MgCl 2 , 2 mM DTT, 0.4 mM PMSF, 1 mM Na 3 VO 4 , and 2 mg/ml each of leupeptin, pepstatin, and aprotinin and spun down at 15,000g for 15 min. Extracts containing 10 mg protein aliquots were incubated for 15 min at ambient temperature with a [
32 P]gATPlabeled probe (3 3 10 4 cpm), together with 500 ng poly dI.dC (Pharmacia) and 100 ng denatured salmon sperm DNA (Sigma) in 20 ml HEPES buffer (pH 7.5, 10 mM), 60 mM KCl, 1 mM MgCl 2 , 2 mM EDTA, 1 mM DTT, and 5% glycerol. The mixtures were then loaded onto 5% nondenaturing PAGE and electrophoresed at 185 V in 0.5 3 TBE (40 mM Tris HCl, 45 mM boric acid, and 2.5 mM EDTA), vacuum dried, and autoradiographed. The ISRE, ISGF3 probe was 59-CCTTCTGAG-GAAAGGAAACCA (from 29,59-oligo A synthetase gene). The serum inducible element (SIE) (GAS), serum inducible factor (SIF) B (Stat1/3), and SIF C (Stat1) probes were 59 GTCGA-CATTTCCCGTAAATC (from ISG-15).
RESULTS
Binding of anti-IFNAR-2 mAb to IFNAR-2
The binding affinities of anti-IFNAR-2 mAb to IFNAR-2 were ascertained in BIAcore studies using soluble IFNAR-2.
As shown in Table 1 At the end of incubation, cells were spun through a layer of phthalate oil, and cell-bound radioactivity was detected using a gamma-counter.
FIG. 2.
Evaluation of anti-IFNAR-2 mAb in the antiviral assay. WISH cells (4 3 10 4 ) were seeded in 96-well flat-bottom plates and cultured overnight. Indicated dilutions of anti-IFNAR-2 mAb were added to wells the next day and preincubated for 2 h at 37°C and 5% CO 2 . An ED 50 dose of HuIFN-a2a and HuIFN-b was subsequently added to test wells. VSV was added 6 h later, and WISH cells were further cultured for 48 h at 37°C and 5% CO 2 . The viral cytopathic effect was determined using MTT staining. 
Effect of anti-IFNAR-2 mAb on type I IFN-mediated biologic activities
We next investigated the ability of anti-IFNAR-2 mAb to neutralize the biologic effects of type I IFN-a1, IFN-a2a, and IFN-b in IFN-mediated antiviral, antiproliferation, MHC class I upregulation, and NK cell cytotoxicity assays. As seen in Figures 2 NK cytotoxicity assay. The ability of anti-IFNAR-2 mAb to modulate type I IFN-induced NK cell cytotoxicity was evaluated in an NK cell line, NK9.2. NK9.2 cells expressed IFNAR-2 on the surface, as judged by FACS staining with anti-IFNAR-2 mAb (data not shown). The ED 100 dose for IFN-a2a (10 4 IU/ml) and IFN-b (10 3 IU/ml) in the NK cell cytotoxicity assay was used for the evaluation of anti-IFNAR-2 mAb. Only anti-IFNAR-2 mAb 51.44 was able to inhibit IFN-a2a and IFNb-induced NK cytotoxicity (Fig. 5) . All other anti-IFNAR-2 mAb tested at concentrations up to 90 mg/ml failed to inhibit NK cell cytotoxicity (data not shown). As anti-IFNAR-2 mAb 51.44 inhibits the binding of IFN-a2a and IFN-b to the IFN receptor, these studies suggest a correlation between inhibition of IFN binding and neutralization of IFN-induced NK cell killing by anti-IFNAR-2 mAb.
Effect of anti-IFNAR-2 mAb on type I IFN-mediated signaling
To determine if the neutralization of type I IFN activity by anti-IFNAR-2 mAb is due to an inhibition of the classic JakStat signaling pathway, tyrosine phosphorylation of Jak1, Tyk2, Stat1, Stat2, Stat3, and ISGF3 binding to ISRE experiments were conducted. Both receptor-blocking (51.44, 234.28) and receptor-nonblocking (117.7) classes of mAb were examined. 6 ; data not shown). mAb 117.7, 53.2, and 35.9 alone did not induce any tyrosine phosphorylation of Jak1 and Tyk2. Thus, the lack of inhibition of Jak1 and Tyk2 tyrosine phosphorylation by mAb 117.7, 53.2, and 35.9 is not likely to be caused by a positive signal by these mAb. Fig. 7 ; data not shown).
ISGF3 and SIF B and SIF C binding to ISRE.
To determine if anti-IFNAR-2 mAb 117.7 mediates its biologic effects by inhibiting ISGF3 and SIF B and SIF C binding to ISRE, gel-shift experiments with mAb 117.7 and 234.28 were conducted. mAb 234.28, which inhibits Jak-Stat tyrosine phosphorylation, also inhibited ISGF3 binding to its ISRE, but mAb 117.7 did not inhibit this binding (Fig. 8, top) . A similar effect with 234.28 and 117.7 mAb was observed for SIF B (Stat1/3 heterodimer) and SIF C (Stat1 homodimer) binding to its ISRE (Fig. 8, bottom) .
IFNAR-1/2 tyrosine phosphorylation.
To investigate if anti-IFNAR-2 mAb affect type I IFN signaling at the receptor level, we evaluated their effects on tyrosine phosphorylation of IFNAR-1 and IFNAR-2. As shown previously by others, the IFN-b-induced association of tyrosine phosphorylated IFNAR-1 and IF-NAR-2 chains was readily detected in the anti-IFNAR-1 immunoprecipitates (confirmed by immunoblotting) (data not shown) (Fig. 9) . (32, 33) The Fig. 9 ; data not shown). Parallel immunoprecipitation and immunoblotting studies with anti-IFNAR-2 antibodies showed that equivalent amounts of IFNAR-2 were being immunoprecipitated in control and 117.7 mAb-treated samples, indicating that hypertyrosine phosphorylation of IFNAR-2 is not due to an increase in immunoprecipitated IFNAR-2 (data not shown).
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DISCUSSION
The current study was undertaken to evaluate if mAb against the IFNAR-2 subunit of the type I IFN receptor could modulate the biologic functions of IFN-a1, IFN-a2a, and IFN-b. All anti-IFNAR-2 mAb evaluated-117.7, 35.9, 53.2, and 51.44-inhibited IFN-a1, IFN-a2a, and IFN-b-mediated antiviral, antiproliferative, and MHC class I upregulation activities, but only receptor-blocking mAb 51.44 inhibited IFN-a2a and IFN-b-induced NK cell cytotoxicity (Table 2) The other class of anti-IFNAR-2 mAb 117.7, 35.9, and 53.2 did not inhibit IFN-a2a and IFN-b binding to its receptor and did not affect Jak-Stat tyrosine phosphorylation but induced hypertyrosine phosphorylation of IFNAR-2.
Interestingly, there is no direct correlation between the ability of anti-IFNAR-2 mAb to block type I IFN binding and their ability to neutralize the biologic effects of IFN in bioassays. As shown in Table 3 , all receptor-blocking (51.44) and receptornonblocking (53.2, 117.7, 35.9) anti-IFNAR-2 mAb were effective in neutralizing most biologic activities of IFN-a1, IFNa2a, and IFN-b. In contrast, a recent report on anti-IFNAR-2 mAb showed that the anti-viral effects of IFN-b are neutralized by only receptor-blocking mAb. (34) The receptor-nonblocking mAb 1D3 used in this study does not neutralize the antiviral effects of IFN-b and inhibits IFN-a only at high doses of mAb. Whereas receptor-nonblocking anti-IFNAR-2 mAb used in our study neutralize the antiviral effects of IFN-a2a at an IC 50 value , 0.02 mg/ml, the 1D3 mAb neutralizes IFN-a1, IFNa2, and IFN-a8-mediated antiviral effects at 500-1000-fold higher doses. Also, Benoit et al. (26) have reported that only the receptor-blocking anti-IFNAR-1 mAb 64G12 was capable of inhibiting the biologic functions of IFN-a2a and IFN-b. Although the nonreceptor-blocking anti-IFNAR-1 mAb 34F10 binds IFNAR-1 with a higher affinity, it failed to show any inhibition of type I IFN biologic functions. The finding from our studies that receptor-nonblocking anti-IFNAR-2 mAb can neutralize most IFN-a and IFN-b biologic functions suggests that these mAb recognize unique epitopes on IFNAR-2 that are involved in signaling and raises the possibility of using this class of mAb as novel therapeutic agents to antagonize multiple species of type I IFN.
The major similarity between the receptor-blocking anti-IFNAR-2 (this study and ref. 34 ) and anti-IFNAR-1 mAb in neutralizing the biologic functions of IFN-a and IFN-b is that they inhibit IFN-a1 and IFN-a2a binding to cells with equivalent potencies and inhibit the Jak-Stat pathway of activation. The anti-IFNAR-2 mAb 51.44 and 234.28 inhibit IFN-a2a and IFN-b-induced tyrosine phosphorylation of Jak1, Tyk2, Stat1/2/3, IFNAR-1, and IFNAR-2 and also inhibit the binding of ISGF3 and Stat1/3 complexes to their ISRE (Figs. 6, 7, 8 , and 9). Although receptor-blocking anti-IFNAR-2 mAb from the Chuntharapai et al. study (34) were tested only in antiviral assays, these mAb also inhibited IFN-a and IFN-b-mediated ISGF3 binding to ISRE. The receptor-blocking anti-IFNAR-1 mAb 64G12 also inhibited IFN-a2a-induced ISGF3 and IFN regulatory factor-1 (IRF-1) binding to their ISRE. (29) The utility of inhibiting the Jak-Stat pathway of activation was proven in skin transplant studies in cynomolgus monkeys using the anti-IFNAR-1 mAb 64G12. (29) In this study, cynomolgus monkeys treated with this mAb and low dose of cyclosporine showed prolonged skin allograft survival for over 300 days in some animals. MHC class I and II expression in grated tissue in animals treated with anti-IFNAR-1 mAb and cyclosporine was significantly inhibited. As the anti-IFNAR-2 mAb 51.44 inhibits MHC class I expression and NK cell activation and has very similar properties to the 64G12 mAb in vitro, it is likely to mediate similar biologic effects in vivo.
Studies with other receptor-blocking anti-IFNAR-1 mAb have shown distinct biologic effects. An independent study using a panel of anti-IFNAR-1 mAb showed that mAb 2E1 and 4A7 inhibited ISGF3 binding and antiviral activity induced by a variety of IFN-a subtypes. (27) However, these mAb did not neutralize the biologic activities of IFN-b. A study by Goldman et al. (28) showed that only anti-IFNAR-1 mAb with receptor-blocking activity, such as EA12 mAb, inhibited IFNa2a-induced Stat activation and showed partial neutralization of antiviral activity. The effects of the EA12 mAb on IFN-bmediated biologic functions were not examined in this study. The differences in IFNAR-1 epitopes recognized by different anti-IFNAR-1 mAb is likely to contribute to the differences observed in inhibiting the biologic effects of both IFN-a and IFNb. In contrast, both receptor-blocking and nonblocking anti-IFNAR-2 mAb evaluated in our study inhibit most biologic functions of IFN-a and IFN-b.
The correlation between inhibition of Jak-Stat activation and neutralization of type I IFN-mediated biologic actions by the 51.44 mAb are consistent with observations implicating Jak1, Tyk2, Stat1/2, and, more recently, Stat3 in mediating the antiviral, antiproliferative, and MHC class I upregulation functions. (35) (36) (37) (38) Embryonic stem cells from Jak1 2/2 and Stat1 2/2 mice showed significantly reduced antiviral and MHC class I upregulation functions and failed to show induction of ISG. (35) (36) (37) Inhibition of NK cell activation by the 51.44 mAb provides evidence that type I IFN signaling in NK cells is uniquely dependent on the Jak-Stat pathway of activation. This is consistent with previous observations that IFN-a2a signaling in NK cells leads to tyrosine phosphorylation of Stat1. (39) The possibility that receptor-nonblocking anti-IFNAR-2 mAb 177.7, 35.9, and 53.2 inhibit type I IFN biologic activities by receptor internalization is unlikely, as [ 125 I]IFN-a2a binding to Daudi cells that were either preincubated with anti-IFNAR-2 mAb 117.7, 35.9, and 53.2 or isotype control mAb for 1-12 h at 37°C (under conditions that could induce receptor internalization) was very similar (data not shown). Moreover, either simultaneous addition or preincubation of WISH cells with anti-IFNAR-2 mAb for 2 h at 37°C showed similar neutralization of IFN-a2a and IFN-b-induced antiviral activity (data not shown).
Our studies on the receptor-nonblocking class of anti-IFNAR-2 mAb provide evidence that other signaling events independent of Jak-Stat tyrosine phosphorylation contribute to antiviral, antiproliferative, and MHC class I upregulation functions of type I IFN. More recent studies on type I IFN signaling have indicated a role for MAPK and PI3 kinase in controlling IFN responses. (18, 19) It is possible that the anti-IFNAR-2 mAb 117.7, 35.9, and 53.2, which do not appear to block Jak-Stat tyrosine phosphorylation, could modulate MAPK and phosphatidylinositol 3 (PI3) kinase pathways of activation. (40) It is possible that mAb 117 could mediate its effects by inhibiting type I IFN-induced p38 MAPK activation and serine phosphorylation of Stat1, which in turn may inhibit the ISG. (41) Alternatively, the 117.7 mAb-induced hyper-tyrosine phosphorylation of IFNAR-2 may contribute to receptor inactivation. Hyper-tyrosine phosphorylation of IFNAR-2 may be a consequence of 117.7 mAb-induced inactivation of a tyrosine phosphatase that is required for signaling. There is evidence that tyrosine phosphatases activate the JakStat signaling, (42, 43) and it is possible that there are tyrosine phosphatases that act on other tyrosine phosphorylation pathways that may also control IFNAR-2 tyrosine phosphorylation. Anti-IF-NAR-2 mAb 117.7 could target these tyrosine phosphatases and induce IFNAR-2 hyper-tyrosine phosphorylation.
In summary, two classes of receptor-blocking and receptornonblocking anti-IFNAR-2 mAb that inhibit the biologic effects of type I IFN via Jak-Stat tyrosine phosphorylation dependent and independent pathways were identified. These studies show that NK cell activation is dependent on Jak-Stat tyrosine phosphorylation, and they more significantly provide support for the existence of other signaling events that control antiviral, antiproliferative, and MHC class I upregulation functions that are independent of Jak-Stat tyrosine phosphorylation. In addition, these studies suggest hyper-tyrosine phosphorylation of IFNAR-2 as a potential mechanism for antagonism of IFN-a/b signaling.
